Compare CTGO & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTGO | BCYC |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.6M | 456.4M |
| IPO Year | 2010 | 2019 |
| Metric | CTGO | BCYC |
|---|---|---|
| Price | $29.16 | $5.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $19.10 |
| AVG Volume (30 Days) | 230.6K | ★ 372.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.12 | 42.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.85 | $5.03 |
| 52 Week High | $34.38 | $11.79 |
| Indicator | CTGO | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 41.61 |
| Support Level | $25.47 | $5.03 |
| Resistance Level | $29.55 | $7.14 |
| Average True Range (ATR) | 1.57 | 0.31 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 74.00 | 47.27 |
Contango Ore Inc operates in the United States. The company is engaged in the exploration of gold, silver, and copper ores in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin whose governmental entity is the Tetlin Tribal Council for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.